Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Incyte Corp Stock Research

INCY

58.56USD+0.50(+0.86%)Market Closed
Watchlist

Market Summary

USD58.56+0.50
Market Closed
0.86%

INCY Alerts

  • 1 major insider sales recently.

INCY Stock Price

INCY RSI Chart

INCY Valuation

Market Cap

13.0B

Price/Earnings (Trailing)

35.38

Price/Sales (Trailing)

3.69

EV/EBITDA

15.48

Price/Free Cashflow

16.6

INCY Price/Sales (Trailing)

INCY Profitability

Operating Margin

93.63%

EBT Margin

14.71%

Return on Equity

7.27%

Return on Assets

5.59%

Free Cashflow Yield

6.02%

INCY Fundamentals

INCY Revenue

Revenue (TTM)

3.5B

Revenue Y/Y

4.74%

Revenue Q/Q

18.05%

INCY Earnings

Earnings (TTM)

366.5M

Earnings Y/Y

26.09%

Earnings Q/Q

837.88%

Price Action

52 Week Range

56.8286.29
(Low)(High)

Last 7 days

-1.2%

Last 30 days

-10.2%

Last 90 days

-6.5%

Trailing 12 Months

-12.9%

INCY Financial Health

Current Ratio

3.95

INCY Investor Care

Shares Dilution (1Y)

0.76%

Diluted EPS (TTM)

1.62

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for INCY

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-01
SWAIN PAULA J
sold
-550,283
65.13
-8,449
evp, human resources
2023-08-01
Stein Steven H
sold
-1,361,220
63.28
-21,511
evp & chief medical officer
2023-07-14
Stamoulis Christiana
acquired
-
-
12,246
evp & chief financial officer
2023-07-14
Tray Thomas
acquired
-
-
6,015
principal accounting officer
2023-07-14
Dhanak Dashyant
acquired
-
-
8,056
evp & chief scientific officer
2023-07-14
Hoppenot Herve
acquired
-
-
43,184
chairman / ceo
2023-07-14
CAGNONI PABLO J
acquired
-
-
9,668
president, r&d
2023-07-14
Stein Steven H
acquired
-
-
13,535
evp & chief medical officer
2023-07-14
Iyengar Vijay K
acquired
-
-
7,089
evp, gmapps
2023-07-14
SWAIN PAULA J
acquired
-
-
7,089
evp, human resources

1–10 of 50

Which funds bought or sold INCY recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-21
Jefferies Group LLC
new
-
6,664,000
6,664,000
0.06%
2023-09-21
Baystate Wealth Management LLC
unchanged
-
-200
1,245
-%
2023-09-20
BARCLAYS PLC
reduced
-11.72
-8,053,000
25,569,000
0.02%
2023-09-12
Farther Finance Advisors, LLC
reduced
-48.15
-2,160
1,743
-%
2023-08-25
Yarbrough Capital, LLC
unchanged
-
-49,999
310,628
0.02%
2023-08-24
Alberta Investment Management Corp
reduced
-21.85
-2,582,790
5,320,010
0.05%
2023-08-22
Old North State Trust, LLC
sold off
-100
-1,000
-
-%
2023-08-22
VIRGINIA RETIREMENT SYSTEMS ET AL
reduced
-28.89
-949,979
1,501,780
0.01%
2023-08-22
COMERICA BANK
new
-
-
-
-%
2023-08-21
OSAIC HOLDINGS, INC.
added
65.25
613,474
2,064,130
-%

1–10 of 46

Latest Funds Activity

Are funds buying INCY calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own INCY
No. of Funds

Schedule 13G FIlings of Incyte

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jun 08, 2023
blackrock inc.
10.5%
23,468,952
SC 13G/A
Mar 15, 2023
baker bros. advisors lp
16.3%
36,280,967
SC 13D/A
Feb 14, 2023
dodge & cox
8.7%
19,362,935
SC 13G/A
Feb 09, 2023
vanguard group inc
9.68%
21,533,818
SC 13G/A
Jan 25, 2023
blackrock inc.
8.9%
19,836,617
SC 13G/A
Mar 10, 2022
baker bros. advisors lp
16.4%
36,269,307
SC 13D/A
Feb 14, 2022
baker bros. advisors lp
15.7%
34,851,571
SC 13D/A
Feb 14, 2022
price t rowe associates inc /md/
3.2%
7,271,688
SC 13G/A
Feb 14, 2022
dodge & cox
7.5%
16,657,586
SC 13G
Feb 10, 2022
vanguard group inc
9.48%
20,944,759
SC 13G/A

Recent SEC filings of Incyte

View All Filings
Date Filed Form Type Document
Sep 12, 2023
8-K
Current Report
Sep 06, 2023
4
Insider Trading
Sep 01, 2023
144
Notice of Insider Sale Intent
Aug 14, 2023
SC 13D/A
13D - Major Acquisition
Aug 03, 2023
4
Insider Trading
Aug 01, 2023
10-Q
Quarterly Report
Aug 01, 2023
144
Notice of Insider Sale Intent
Aug 01, 2023
8-K
Current Report
Jul 18, 2023
4
Insider Trading
Jul 18, 2023
4
Insider Trading

INCY Fair Value

Loading...

Peers (Alternatives to Incyte)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
92.4B
27.4B
-3.33% 22.27%
16.85
3.37
-0.48% 32.56%
39.4B
10.7B
-8.22% -12.63%
32.61
3.69
-53.67% -91.41%
13.0B
3.5B
-10.25% -12.88%
35.38
3.69
5.81% -61.22%
12.0B
2.3B
-21.99% 104.46%
-27.78
5.21
18.69% 41.23%
MID-CAP
7.1B
1.7B
-2.29% 41.71%
43.33
4.15
10.25% -39.75%
4.5B
5.4B
1.03% -7.57%
62.57
0.82
0.01% -74.39%
2.8B
256.2M
-6.12% -20.57%
-15.52
10.97
2.51% -17.66%
2.7B
-
-15.10% -35.52%
-21.18
37.44
122.90% 54.78%
SMALL-CAP
668.6M
1.6B
-13.64% -61.04%
-1.14
0.42
23.74% 60.24%
517.6M
-
-19.90% -38.37%
-10.02
6.7K
- -13.75%
329.6M
22.1M
-28.73% -39.15%
14.88
14.91
43.14% 124.16%
170.9M
66.2M
-71.28% -88.95%
-0.25
2.73
20.37% -7.56%
15.7M
-
-6.90% -21.97%
-2.32
-
- 19.06%
7.1M
559.4K
-13.48% -91.21%
-0.37
12.75
- 69.86%

Incyte News

StreetInsider.com
Form 4 INCYTE CORP For: Sep 29 Filed by: Baker Brothers Life ....
StreetInsider.com,
43 minutes ago
MarketWatch
Best Stocks
Digital Journal

Returns for INCY

Cumulative Returns on INCY

3.8%


10-Year Cumulative Returns

-6.9%


7-Year Cumulative Returns

-3.6%


5-Year Cumulative Returns

-13.2%


3-Year Cumulative Returns

Risks for INCY

What is the probability of a big loss on INCY?

74.2%


Probability that Incyte stock will be more than 20% underwater in next one year

14.6%


Probability that Incyte stock will be more than 30% underwater in next one year.

1.5%


Probability that Incyte stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does INCY drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Incyte was unfortunately bought at previous high price.

Drawdowns

Financials for Incyte

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Last 12 Months)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue1.2%3,513,2863,470,0733,394,6353,330,7883,320,4723,114,7842,986,2672,912,9232,720,5792,702,9132,666,7022,456,5822,387,5202,229,4092,158,7592,107,7722,005,8741,997,4581,881,8831,797,6371,729,488
Costs and Expenses3.5%3,086,2672,982,4032,815,1952,710,7072,603,3572,511,2642,400,4902,273,6512,311,3912,203,7882,930,3782,789,4792,591,4272,565,4771,756,7531,718,7991,720,0981,727,0551,752,6601,882,8071,830,758
  S&GA Expenses2.8%1,138,8141,108,1621,002,140955,523879,767795,349739,560680,346610,430559,569516,922486,111467,931455,876468,711440,892434,806436,892434,407423,775418,518
  R&D Expenses3.3%1,692,7581,639,2041,585,9361,557,4031,508,3411,504,6561,458,1791,391,2971,494,4611,437,5512,215,9422,122,8641,966,0911,968,8531,154,1111,145,4821,156,6731,165,3991,197,9571,340,5901,317,620
EBITDA-100.0%-583,520599,637635,767694,445634,330630,196676,262461,648595,658-178,237-219,977-67,484-265,520543,179------
EBITDA Margin-100.0%-0.17*0.18*0.19*0.21*0.20*0.21*0.23*0.17*0.22*-0.07*-0.09*-0.03*-0.12*0.25*------
Interest Expenses-0.9%2,4322,4552,6662,7512,5492,2291,9081,5841,6891,9312,1742,3532,4062,1221,8551,6031,4111,4931,5431,5611,360
Earnings Before Taxes9.4%558,663510,437529,116568,521629,402571,657570,444618,526405,549541,180-232,218-274,316-122,789-321,382486,791431,504314,461259,798115,347-103,647-91,269
EBT Margin-100.0%-0.15*0.16*0.17*0.19*0.18*0.19*0.21*0.15*0.20*-0.09*-0.11*-0.05*-0.14*0.23*------
Net Income13.0%366,487324,371340,660876,050945,014933,038948,581534,580337,638478,480-295,697-334,542-191,068-376,048446,906404,964305,869252,945109,493-109,199-102,321
Net Income Margin-100.0%-0.09*0.10*0.26*0.28*0.30*0.32*0.18*0.12*0.18*-0.11*-0.14*-0.08*-0.17*0.21*------
Free Cashflow-100.0%-648,597969,941801,630760,347759,134749,488741,458668,475764,913-124,599-100,302-12,002-128,424710,656------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets7.1%6,2085,7985,8415,5105,3195,0544,9334,1993,9053,6613,5613,3073,2122,7523,4273,2152,9482,7542,6462,5202,397
  Current Assets7.4%4,2643,9724,0933,8213,6263,2883,1192,9242,6202,4502,3602,1592,0781,7162,4812,3202,0591,9051,8321,7001,598
    Cash Equivalents11.0%3,1312,8212,9512,6912,4372,2582,0592,0011,7991,6721,5151,5001,3291,0461,8341,7031,4171,3011,1651,113930
  Inventory-12.2%36.0041.0042.0046.0055.0035.0028.0021.0017.0017.0016.0017.0016.0014.0011.007.007.007.007.006.006.00
  Net PPE1.0%749742739716721729724687661595560498454410378347339338320301268
  Goodwill0%156156156156156156156156156156156156156156156156156156156156156
Liabilities9.9%1,4681,3351,4711,2841,2341,1911,1631,050969934950917868815828792700669720717664
  Current Liabilities11.2%1,1191,0061,1571,007927886854743660624631606557503513462367365425422368
Shareholder's Equity6.2%4,7414,4634,3704,2274,0853,8633,7703,1492,9362,7282,6112,3912,3451,9382,5982,4232,2472,0861,9261,8031,733
  Retained Earnings49.0%-211-415-437-465-578-739-777-1,341-1,523-1,672-1,726-1,876-1,861-2,151-1,430-1,541-1,670-1,775-1,877-1,946-1,976
  Additional Paid-In Capital1.4%4,9264,8574,7924,7214,6894,6264,5674,5094,4774,4214,3534,2774,2184,1024,0443,9733,9263,8703,8143,7593,719
Shares Outstanding0.1%223223223222222221221221220220219219218217216215215214213213212
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations20.4%781649970802760759749741668765-124-100-12.00-12871166359247133616317.00
  Share Based Compensation4.1%206198188184181179183180181183178175174169167162157153148145142
Cashflow From Investing5.6%-85.30-90.35-78.54-123-128-164-207-244-226-220-269-196-169-171-87.45-93.52-123-82.46-86.42-193-206
Cashflow From Financing-97.2%0.003.00-0.7911.006.00-6.566.009.0029.0082.0072.0089.0091.0044.0046.0020.0020.0017.0015.0014.00666

INCY Income Statement

2023-06-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenues:    
Total revenues$ 954,610$ 911,397$ 1,763,283$ 1,644,632
Costs and expenses:    
Cost of product revenues (including definite-lived intangible amortization)68,32650,636125,14893,250
Research and development400,750347,196807,391700,569
Selling, general and administrative283,929253,277599,535462,861
Loss on change in fair value of acquisition-related contingent consideration8,3743,31314,5709,695
(Profit) and loss sharing under collaboration agreements(549)2,544(1,911)7,286
Total costs and expenses760,830656,9661,544,7331,273,661
Income from operations193,780254,431218,550370,971
Interest income and other, net42,66852275,5411,782
Interest expense(655)(678)(1,124)(1,358)
Unrealized gain (loss) on long term investments41,811(24,897)36,493(71,482)
Income before provision for income taxes277,604229,378329,460299,913
Provision for income taxes74,05667,946104,209100,489
Net income$ 203,548$ 161,432$ 225,251$ 199,424
Net income per share:    
Basic (in USD per share)$ 0.91$ 0.73$ 1.01$ 0.90
Diluted (in USD per share)$ 0.90$ 0.72$ 1.00$ 0.89
Shares used in computing net income per share:    
Basic (in shares)223,248221,660223,104221,493
Diluted (in shares)225,649223,661225,541223,277
Product revenues, net    
Revenues:    
Total revenues$ 827,005$ 663,851$ 1,520,242$ 1,269,672
Product royalty revenues    
Revenues:    
Total revenues127,605117,546243,041239,960
Milestone and contract revenues    
Revenues:    
Total revenues$ 0$ 130,000$ 0$ 135,000

INCY Balance Sheet

2023-06-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
[1]
Current assets:  
Cash and cash equivalents$ 3,131,123$ 2,951,422
Marketable securities—available-for-sale (amortized cost $294,371 and $292,580 as of June 30, 2023 and December 31, 2022, respectively; allowance for credit losses $0 as of June 30, 2023 and December 31, 2022)292,243287,543
Accounts receivable637,994644,879
Inventory35,93741,995
Prepaid expenses and other current assets167,136167,011
Total current assets4,264,4334,092,850
Restricted cash1,7191,698
Long term investments170,316133,676
Inventory142,04878,964
Property and equipment, net749,352739,310
Finance lease right-of-use assets, net25,63126,298
Other intangible assets, net134,954129,219
Goodwill155,593155,593
Deferred income tax asset532,507457,941
Other assets, net31,70625,435
Total assets6,208,2595,840,984
Current liabilities:  
Accounts payable155,538277,546
Accrued compensation111,708138,761
Accrued and other current liabilities810,852701,053
Finance lease liabilities3,1663,179
Acquisition-related contingent consideration37,50936,538
Total current liabilities1,118,7731,157,077
Acquisition-related contingent consideration179,491184,462
Finance lease liabilities29,49130,083
Other liabilities139,81299,243
Total liabilities1,467,5671,470,865
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, $0.001 par value; 5,000,000 shares authorized; none issued or outstanding00
Common stock, $0.001 par value; 400,000,000 shares authorized; 223,338,330 and 222,746,719 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively223223
Additional paid-in capital4,925,6264,792,041
Accumulated other comprehensive income26,80615,069
Accumulated deficit(211,963)(437,214)
Total stockholders’ equity4,740,6924,370,119
Total liabilities and stockholders’ equity$ 6,208,259$ 5,840,984
[1]The condensed consolidated balance sheet at December 31, 2022 has been derived from the audited consolidated financial statements at that date.
Herve Hoppenot
2090
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.